Markets finish week down after bouncing on Bannon's exit >>> READ MORE

5 Pharma Stocks to Buy for Big Dividends

Don't assume pharmaceutical companies can't offer attractive dividends

      View All  

Eli Lilly

dividends-stocks-LLYDespite the recent expiration of its best-selling drug, Cymbalta, in addition to the clock ticking on Evista and the no-longer-patent-protected Humalog, it’s too soon to count Eli Lilly (LLY) out, and it’s too soon to assume its 3.9% dividend yield is going to evaporate.

See, Eli Lilly’s got five drugs currently being reviewed for approval by the FDA, and eight more therapies in phase 3 trials. None of them are apt to be the blockbuster Cymbalta is. In fact, statistically speaking, some of those drugs will ultimately be rejected or fail to meet their end goals.

In the aggregate though, the combination of the ones that cross the finish line could effectively replace the $5 billion in sales Cymbalta generated for Lilly in 2012. That means LLY can keep pumping out the dividends.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC